Aarti Drugs Limited has informed the Exchange about General Updates
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Drugs Limited will invest Rs. 10 Crore in its wholly owned subsidiary Pinnacle Life Science Private Limited by subscribing to a rights issue of 78,125 equity shares (face value Rs. 10, premium Rs. 1,270 per share). The funds will be used by Pinnacle for expansion/capex and general corporate purposes. Pinnacle is a pharmaceutical formulations maker with a portfolio spanning oncology, cardiovascular, anti-infectives, and diabetics, exporting to over 30 countries. Its turnover stood at Rs. 25,392.38 Lakhs in FY25, down from Rs. 31,465.76 Lakhs in FY24. Share allotment is expected on or before March 20, 2026, and Pinnacle will continue to remain a wholly owned subsidiary.
This is a capital infusion into an existing wholly owned subsidiary rather than a new acquisition, so there is no change in ownership or control. For shareholders, the move signals continued investment in the subsidiary's growth and capex plans, though the relatively modest Rs. 10 Crore size limits any material impact on Aarti Drugs' consolidated financials.